Jon Beauchamp

440 total citations
9 papers, 291 citations indexed

About

Jon Beauchamp is a scholar working on Neurology, Hematology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jon Beauchamp has authored 9 papers receiving a total of 291 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Neurology, 4 papers in Hematology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jon Beauchamp's work include Myasthenia Gravis and Thymoma (4 papers), Blood groups and transfusion (3 papers) and Parkinson's Disease and Spinal Disorders (3 papers). Jon Beauchamp is often cited by papers focused on Myasthenia Gravis and Thymoma (4 papers), Blood groups and transfusion (3 papers) and Parkinson's Disease and Spinal Disorders (3 papers). Jon Beauchamp collaborates with scholars based in United States, United Kingdom and Belgium. Jon Beauchamp's co-authors include Domenica Gandini, Nataliya Romanyuk, E. Sally Ward, Blanca Sánchez‐González, Marie Godar, Adrian C. Newland, Katrien Verschueren, László Rejtő, Howard A. Liebman and David J. Kuter and has published in prestigious journals such as Blood, Neurology and British Journal of Haematology.

In The Last Decade

Jon Beauchamp

9 papers receiving 281 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jon Beauchamp United States	7	119	114	65	55	51	9	291
Hollie M. Reeves United States	9	98 0.8×	93 0.8×	77 1.2×	47 0.9×	39 0.8×	15	311
Viviani Pessôa Brazil	4	225 1.9×	115 1.0×	29 0.4×	116 2.1×	15 0.3×	8	314
Idris Boudhabhay France	9	107 0.9×	92 0.8×	11 0.2×	105 1.9×	8 0.2×	30	298
Shipra Kaicker United States	7	34 0.3×	93 0.8×	47 0.7×	18 0.3×	12 0.2×	11	198
Robert Greiner United States	5	92 0.8×	65 0.6×	13 0.2×	47 0.9×	19 0.4×	22	218
Jean‐Charles Crave France	10	143 1.2×	71 0.6×	53 0.8×	49 0.9×	43 0.8×	16	290
F. Pasquet France	7	47 0.4×	19 0.2×	158 2.4×	24 0.4×	18 0.4×	30	293
P Lavilla Spain	6	82 0.7×	50 0.4×	44 0.7×	10 0.2×	41 0.8×	19	298
Sara Signa Italy	11	107 0.9×	32 0.3×	42 0.6×	26 0.5×	25 0.5×	28	288
Elaine Yu United States	8	79 0.7×	76 0.7×	10 0.2×	53 1.0×	34 0.7×	15	329

Countries citing papers authored by Jon Beauchamp

Since Specialization

Citations

This map shows the geographic impact of Jon Beauchamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Beauchamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Beauchamp more than expected).

Fields of papers citing papers by Jon Beauchamp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Beauchamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Beauchamp. The network helps show where Jon Beauchamp may publish in the future.

Co-authorship network of co-authors of Jon Beauchamp

This figure shows the co-authorship network connecting the top 25 collaborators of Jon Beauchamp. A scholar is included among the top collaborators of Jon Beauchamp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon Beauchamp. Jon Beauchamp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Gwathmey, Kelly, Catherine M. Broome, Matthias Goebeler, et al.. (2025). Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases. Expert Review of Clinical Immunology. 21(5). 627–638. 3 indexed citations

Berrih‐Aknin, Sonia, Jacqueline Palace, Andreas Meisel, et al.. (2023). Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG). BMJ Open. 13(5). e068104–e068104. 10 indexed citations

Dewilde, Sarah, Jon Beauchamp, Silvia Chiroli, et al.. (2023). Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ Open. 13(1). e066445–e066445. 20 indexed citations

Berrih‐Aknin, Sonia, Kristl G. Claeys, Nancy Law, et al.. (2021). Patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG). BMJ Open. 11(7). e048198–e048198. 15 indexed citations

Howard, James F., Vera Bril, Renato Mantegazza, et al.. (2020). Additional Analyses of the Phase 2 Efgartigimod Study in Myasthenia Gravis (4484). Neurology. 94(15_supplement). 1 indexed citations

Newland, Adrian C., Blanca Sánchez‐González, László Rejtő, et al.. (2019). Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia. Blood. 134(Supplement_1). 895–895. 9 indexed citations

Newland, Adrian C., Blanca Sánchez‐González, László Rejtő, et al.. (2019). Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. American Journal of Hematology. 95(2). 178–187. 129 indexed citations

Kelly, Richard, Louise Arnold, Stephen J. Richards, et al.. (2010). The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. British Journal of Haematology. 149(3). 446–450. 86 indexed citations

Beauchamp, Jon, et al.. (2002). Delayed valproic acid toxicity: A retrospective case series. Annals of Emergency Medicine. 39(6). 616–621. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact